UPDATE: Chardan Capital Starts Amarin Corporation (AMRN) at Neutral, Chance of Strategic Deal Low

March 20, 2013 8:14 AM EDT Send to a Friend
Get Alerts AMRN Hot Sheet
Price: $1.26 +3.28%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 23
Trade AMRN Now!
Join SI Premium – FREE
(Updated - March 20, 2013 11:17 AM EDT)

Chardan Capital initiates coverage on Amarin Corporation (NASDAQ: AMRN) with a Neutral with a price target of $8.50. Analyst Andrew Fein said Amarin chance for near-term strategic deal is low.

Fein also said the company faced risks from a slow Vascepa debut. A survey showed curbed enthusiasm for Vascepa and an undifferentiated clinical profile compared to three other therapies.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $7.93 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Comments

Survey's??????????
James Peterson on 2013-03-20 14:41:33
Mark as Spam | Reply to this comment

What survey's??????? What competition??? You seem to be the only company that has that???
Every survey that has been done by a reputable Entity and is public knowledge in the last 3 years all CONTRADICT what your survey says... So tell the world what survey and where people can find it?? LINK..
Fact is everything you wrote is BS. And it will be forwarded to the proper people to handle it.

Remarks on Report
Vincent Mazza on 2013-03-20 12:10:47
Mark as Spam | Reply to this comment

After reading your report today there are many errors and questions I have. First I have followed AMRN for the last 3 years. In that time frame this company has hit every milestone and more on time. The drugs trials and data under the SPA agreement with the FDA exceeded expectations in ALL markets and Indications. It is the first drug that will enter both the ANCHOR mkt and Combo-Statin. All the facts and data proves that. As far as the drug launch its been only 7 weeks, scripts have been growing and they are ahead of where Lovaza was after 7 weeks of launching. And as far as a deal is concerned NO ONE knows but AMRN and the Pharma Companies involved.
There is zero competition in the other mkts outside of Marine and if you think Big Pharma doesn't want a drug that works the way Vascepa does with a very safe side effect profile, going into a market 10 x's larger then the comp all ALONE, you are incorrect.
It seems you have jumped into AMRN very late in the game with little knowledge backing what your claims are. 90% of this report is misleading and incorrect.
If you have any facts NOT Opinion to back up your claims I would love to hear them.
However, it is not right to mislead investors the way you have and this is a part of the Industry that needs to be regulated more. Especially when the Street Insider's info is posted all over each financial site. My # is below.
(888) 544-5244


Add Your Comment